Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	5,239	10,369	10,504	6,795	5,988	3,109
Short-Term Investments	1,285	849.2	274.5	729.9	670.7	698.97
Cash & Short-Term Investments	6,525	11,218	10,779	7,525	6,659	3,808
Cash Growth	-45.30%	4.08%	43.24%	13.01%	74.85%	20.20%
Accounts Receivable	1,751	1,563	1,442	1,137	885.4	633.52
Receivables	1,751	1,563	1,442	1,137	885.4	633.52
Inventory	1,080	738.8	460.6	353.1	280.8	167.5
Prepaid Expenses	438.7	537.6	431.6	442.1	228.6	195.79
Restricted Cash	8.9	-	-	5.1	0.7	8
Other Current Assets	1.6	86.1	121.9	98.6	79	9.73
Total Current Assets	9,804	14,144	13,235	9,561	8,133	4,823
Property, Plant & Equipment	2,514	1,453	1,456	1,424	1,284	833.28
Long-Term Investments	4,778	2,596	112.2	-	-	-
Goodwill	1,088	1,088	1,088	1,002	1,002	1,002
Other Intangible Assets	831.6	839.9	603.6	400	400	400
Long-Term Deferred Tax Assets	2,309	1,812	1,247	934.5	882.8	1,191
Long-Term Deferred Charges	-	58.9	40.2	-	-	-
Other Long-Term Assets	916.1	737.8	369.4	110.8	49.3	69.38
Total Assets	22,240	22,730	18,151	13,433	11,752	8,318
Accounts Payable	395.8	364.9	303.9	195	155.1	87.61
Accrued Expenses	3,220	2,556	2,003	1,467	1,301	1,045
Current Portion of Leases	71.2	83.7	89.4	80.2	52.9	50.3
Current Income Taxes Payable	-	99.5	123.3	211.3	104.2	72.29
Current Unearned Revenue	220	170.3	159.6	171.7	191.5	62.33
Other Current Liabilities	66.4	273.2	62.5	16.5	73	17.68
Total Current Liabilities	3,973	3,547	2,742	2,142	1,878	1,335
Long-Term Leases	1,703	724.7	810.3	887.2	889.5	622.87
Other Long-Term Liabilities	933.3	877.7	685.8	303.3	298	275.53
Total Liabilities	6,609	5,150	4,238	3,333	3,065	2,233
Common Stock	2.6	2.6	2.6	2.5	2.6	2.59
Additional Paid-In Capital	6,906	7,450	7,387	6,881	7,894	7,938
Retained Earnings	8,694	10,142	6,523	3,201	858.7	-1,853
Comprehensive Income & Other	28.8	-14.3	0.8	15.9	-68.5	-1.97
Total Common Equity	15,631	17,580	13,913	10,100	8,687	6,085
Shareholders' Equity	15,631	17,580	13,913	10,100	8,687	6,085
Total Liabilities & Equity	22,240	22,730	18,151	13,433	11,752	8,318
Total Debt	1,774	808.4	899.7	967.4	942.4	673.17
Net Cash (Debt)	9,454	12,908	9,991	6,558	5,717	3,135
Net Cash Growth	-26.62%	29.19%	52.36%	14.71%	82.34%	21.45%
Net Cash Per Share	36.64	49.55	38.56	25.23	21.70	12.03
Filing Date Shares Outstanding	257.53	258.31	257.09	254.58	259.96	259.27
Total Common Shares Outstanding	257.74	257.7	257.01	254.48	259.89	258.99
Working Capital	5,831	10,597	10,493	7,419	6,256	3,488
Book Value Per Share	60.65	68.22	54.13	39.69	33.42	23.50
Tangible Book Value	13,711	15,653	12,221	8,698	7,285	4,683
Tangible Book Value Per Share	53.20	60.74	47.55	34.18	28.03	18.08
Land	-	33.1	33.1	33.1	33.1	-
Buildings	-	928.6	903.1	892.5	876.1	713.41
Machinery	-	911.9	788.6	701	605.3	548.44
Leasehold Improvements	-	474.6	410.9	363.5	234.6	175.77

Source: S&P Capital IQ. Standard template. Financial Sources.